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Abstract
Efficient and reliable assessments of cognitive treatment effects are essential for the comparative
evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the
sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before
and after treatment. Participants were primarily first episode schizophrenia patients who
completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief
Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of
Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine,
quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both
batteries was characterized by a single factor of generalized cognitive deficit for both baseline
performance and cognitive change after treatment. Both batteries estimated similar levels of
change following treatment, although the BACS battery required half the administration time.
Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as
cognitive change after treatment with atypical antipsychotic medications, short batteries such as
the BACS may efficiently provide sufficient assessment of procognitive treatment effects with
antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting
specific cognitive domains or impairments may require more extensive testing of the domains
targeted to maximize sensitivity for detecting specific predicted cognitive outcomes.
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INTRODUCTION
Generalized cognitive deficits have been well documented in schizophrenia and are
considered core features of the disorder (Bilder et al., 2000; Blanchard & Neale, 1994; Gold
et al., 1992; Hill et al., 2001; Saykin et al., 1991). Moderate to marked deficits are typically
seen across a wide range of cognitive abilities, are present during the first episode of
psychosis, and endure after pharmacological treatment (Hill et al., 2004a; Hoff et al., 1999).
Moreover, cognitive deficits have been linked with long-term functional disability (Green,
1996). As a result, cognitive enhancement has been recognized as an important treatment
target in schizophrenia.
Evaluation of the procognitive effects of atypical relative to typical antipsychotics has
indicated somewhat greater benefit with atypical compared with typical antipsychotics
(Bilder et al., 2002; Green et al., 2002; Harvey et al., 2000; Keefe et al., 1999; Purdon et al.,
2000). In general, modest cognitive benefits from antipsychotic medications are
characterized by reduction of generalized cognitive deficits across a wide range of abilities,
rather than particular effects on a specific neuropsychological domain (Buchanan et al.,
1994; Cassens et al., 1990; Hill et al., 2004a; Rollnik et al., 2002).
Evaluating the cognitive benefits of treatments requires reliable, valid, and efficient
assessment procedures. The cost of testing in large clinical trials and limited cooperation of
schizophrenia patients are both motivators for developing brief efficient batteries, yet the
degree to which shorter batteries may have reduced sensitivity to treatment effects is an
opposing concern. In recent years, several brief test batteries have been developed for
assessing cognition in clinical trials of antipsychotic medications in schizophrenia. One of
these, the Brief Assessment of Cognition in Schizophrenia (BACS: Keefe et al., 2004),
requires less than 35 min to administer and has an excellent completion rate and high
reliability (Keefe et al., 2004). A second battery was developed and used in the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) project (Keefe et al., 2006).
This was the first large community trial designed to evaluate the comparative effectiveness
of different antipsychotic treatments for schizophrenia (Keefe et al., 2003). Tests for the
CATIE battery were selected, in part, based on their sensitivity to known deficits in the
disorder as well as the relation of measured deficits to outcome variables such as community
function (Keefe et al., 2003). No prior studies have compared these or other batteries in
terms of sensitivity and efficiency for estimating both cognitive abilities and change in
cognitive performance during clinical trials.
Consistent with the wide use of atypical or “second generation” antipsychotics in first
episode patients, the Comparison of Atypicals in First Episode schizophrenia (CAFE) study
compared three atypical agents (olanzapine, quetiapine, and risperidone) in the treatment of
first episode and early course schizophrenia with cognitive change as a secondary outcome
as measured by the CATIE and BACS batteries. This provided a rare opportunity to directly
compare the psychometrics, utility, and efficiency of two neuropsychological batteries in a
clinical trial setting.
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The CAFE study compared the effectiveness of atypical antipsychotics in a randomized
double-blind clinical trial across 26 sites. Details of the study design and direct comparison
of tolerability and efficacy of olanzapine, quetiapine, and risperidone have been presented
elsewhere (Keefe et al., 2003, 2007). The protocol was approved by the local internal review
boards, and each participant provided written informed consent.
Participants
Patients were recruited who had recently experienced an episode of acute psychosis that
required treatment initiation and met Diagnostic and Statistical Manual for Mental
Disorders-IV (DSM-IV; American Psychiatric Association, 1987/1994) criteria for
schizophreniform, schizophrenia, or schizoaffective disorder based on Structured Clinical
Interview for DSM-IV (SCID; First et al., 1995). Patients were excluded if they had been ill
for more than 5 years or had prior lifetime antipsychotic treatment for 16 cumulative weeks.
Other exclusion criteria included non-English speaking, mental retardation, unstable medical
conditions, pregnancy or nursing, serious head injury, neurologic disease, substance abuse
(past 3 months), past substance dependence, and systemic disorders known to affect brain
function. At baseline, 400 patients were randomized to treatment with olanzapine (2.5–20
mg/day), quetiapine (100–800 mg/day), or risperidone (0.5– 4 mg/day). Before study
enrollment, 76% of participants were exposed to antipsychotic treatments for a median of 4
weeks (range, <1–52). Any previous antipsychotic therapy was tapered and discontinued
during the first 2-weeks of double-blind treatment, and no subsequent use of an additional
antipsychotic was allowed. Treatment with adjunctive antidepressants or mood stabilizers
were not allowed during the first 8-weeks of treatment. Anticholinergic medications were
permitted for a total of 2 weeks and low doses were encouraged. This strategy resulted in
limited (<5%) use of benzodiazepines, antidepressants, mood stabilizers, and
anticholinergics. Of the 219 participants who completed the 12-week cognitive assessments
35.6% (n = 78) were assigned olanzapine, 31.5% (n = 69) to quetiapine, and 32.9% (n = 72)
to risperidone. Because there were no significant group differences on global cognitive
performance for the atypical antipsychotics at baseline or the 12-week follow-up (Keefe et
al., 2007), data were pooled across treatment conditions for the statistical analysis.
Clinical Assessments
The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) and Clinical Global
Impression scale (CGI; Guy, 1976) were used to assess psychopathology. All patients had
ratings of ≥4 on at least one PANSS psychosis item at the point of maximum severity of
illness to date. Social and occupational function were evaluated with the Heinrichs-
Carpenter Quality of Life Scale (QLS), and the impact of insight on treatment adherence
was evaluated using the Insight into Treatment and Attitudes Questionnaire (ITAQ). As
detailed in a separate report, symptom reduction was substantial in each treatment group,
while improvements in social and vocational function were small (<0.2 SDs) after 12 weeks
of treatment (McEvoy et al., 2007).
Neurocognitive Measures
Baseline cognitive assessments were conducted before initiation of study treatment. The
CATIE battery was the primary cognitive measure. This battery requires approximately 90
min to administer 10 tests that characterize six neuropsychological domains (see Keefe et
al., 2003, 2006). The BACS can be administered in 35 min and consists of six tests covering
four domains (Keefe et al., 2004). The CATIE battery was always administered before the
BACS. In the CATIE battery, alternate forms were available for the Hopkins Verbal
Learning Test. Alternate forms for the BACS List Learning test were the same as the final
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versions described in the BACS validation report (Keefe et al., 2004). Alternate forms were
also used for the Tower Test. The BACS validation study showed that alternate Verbal
Fluency forms were not needed (Keefe et al., 2004); thus, subsequent BACS versions did
not include alternate Verbal Fluency forms. The BACS Category Instance Generation (CIG)
test was administered at baseline; however, the alternate version was redundant with the
CATIE battery at follow-up, and the BACS CIG was consequently excluded from all data
analysis. Each tester held a doctoral degree or was supervised by a PhD-level psychologist,
had previous testing experience, and demonstrated testing competence during training.
Neurocognitive assessments were completed at baseline, 12-weeks, and 52-weeks/
termination. Comparison of the cognitive batteries was restricted to baseline and 12-week
data because of greater attrition at 52-weeks. Of the 400 patients enrolled in the study,
4.25% were not administered cognitive tests. Two patients were excluded due to extremely
deficient baseline scores. Of the 16 CATIE/BACS tests 9.4% patients had missing data for
one test, 3.4% for two tests, 1.0% for three tests, and an additional 2.6% for four or more
tests. Missing data on a maximum of two tests was selected as the criterion for inclusion in
the analyses, and baseline exploratory factor analyses were thus limited to 367 patients.
Missing data points were imputed by means of linear regression using available
neurocognitive data to predict missing values. At the 12-week follow-up, 222 patients were
administered both cognitive batteries. Consistent with the criterion of 2 or fewer missing
tests for inclusion, another 3 patients were excluded from the follow-up analyses.
Computation of within-subject effect size of change, exploratory factor analysis of change
scores, and regression analysis was restricted to a sample of 219 patients. As can be seen in
Tables 1 and 2, the follow-up sample was well matched to the baseline sample in terms of
demographics and neuropsychological performance. Change scores were computed as the
difference between performance at baseline and 12-weeks for each of the 10 domain scores
provided by the two test batteries.
In the absence of a matched control group, it is difficult to make inferences regarding the
level of cognitive deficit in this sample. However, to provide an approximate
characterization of the current sample in terms of overall cognitive level, we compared
BACS performance to previously published data on a healthy comparison sample (co-
normed data are not available for the CATIE battery). Composite scores for the BACS were
calculated as the mean of Z scores, separately computed for each measure relative to the
mean and standard deviation of the healthy comparison sample used in the BACS validation
study (Keefe et al., 2004). Consistent with previous reports characterizing first episode
samples relative to healthy comparison samples with other batteries (Bilder et al., 2000; Hill
et al., 2004a), the BACS composite indicated moderate overall cognitive impairment for
participants who completed baseline (Z =−1.54 ±0.93) and 12-week (=−1.49 ±0.92)
assessments.
Data Processing and Plans for Analysis
To provide a standard metric for combining test scores into domains and comparing
performance over time, test scores were standardized (converted to Z scores) relative to the
baseline sample. When necessary, skewed or kurtic distributions were normalized using log
[Wisconsin Card Sorting Test (WCST): perseverative errors; Computerized Visuospatial
Working Memory Test: mean delay minus no delay error] or cube (Penn Emotion
Discrimination Test) transformations before computing Z scores. Scores for each domain
were computed as the mean of Z scores within that neurocognitive domain (Saykin et al.,
1991).
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Decision-Making Processes in Exploratory Factor Analysis
Exploratory rather than confirmatory factor analysis was used because no previous study has
evaluated the factor structure of cognitive change scores after antipsychotic treatment.
Additionally, exploratory factor analysis is an empirically driven technique that places fewer
constraints on the data and maximizes the likelihood of detecting differences in the factor
structure of the CATIE and BACS batteries, should differences exist. Exploratory factor
analysis has been used for a variety of applications in the social sciences. Based on well-
established guidelines (Gorsuch, 1983; Loehlin, 1992) and recent “best practices”
recommendations (Costello & Osborne, 2005), a conservative approach to exploratory factor
analysis was used to obtain results that are likely to generalize to other samples. The
following is a detailed rationale of our decision making with regard to the four major steps
in exploratory factor analysis.
Power and Sample Size
Exploratory factor analysis is a large sample procedure typically appropriate for samples
greater than 100. Conventional guidelines recommend samples with subject to variable
ratios of 10:1 or greater, while more liberal guidelines state that a ratio of 5:1 may be
sufficient in some cases. The most replicable results are obtained with a subject to variable
ratio of 20:1 or greater (Costello & Osborne, 2005), and all factor analyses presented in this
report exceeded a 20:1 ratio.
Extraction Method
Principal components analysis (PCA), maximum likelihood, and principal axis factoring
(PAF) are widely researched (Gorsuch, 1990; Loehlin, 1990) extraction methods. PCA can
best be classified as a data reduction technique whose computations are applied without
regard to underlying structure caused by latent variables (Loehlin, 1990). Specifically,
components are calculated using all variance rather than separating shared and unique
variance. Thus, PCAmay produce inflated values of explained variance relative to true factor
analysis methods (Gorsuch, 1997).
Assumptions regarding normality of multivariate distributions also influenced selection of
extraction method, because a small number of CATIE tests required algebraic
transformations to normalize distributions (yet all domain scores were normally distributed).
Although most factor extraction techniques (i.e., maximum likelihood) are generally robust
to non-normally distributed data (Fabrigar et al., 1999), we reported results of principal axis
factoring, because it is robust to violations of multivariate normality (Costello & Osborne,
2005). However, to evaluate possible bias resulting from the selected extraction technique,
we compared PCA, maximum likelihood, and PAF methods and all three extraction methods
yielded similar results.
Number of Factors to Retain
After extraction, one must determine the number of factors to retain. The default in most
software packages is the Kaiser criterion, which recommends that all factors with
eigenvalues greater than 1.0 be retained. However, this is merely the first step in selecting
the number of factors to retain because strict adherence to this guideline is “among the least
accurate methods” for selecting a factor solution (Velicer & Jackson, 1990). The scree test
better estimates the degree to which keeping/adding factors accounts for variance in the data
(Costello & Osborne, 2005). Thus, we used the Kaiser criterion to indicate the maximum
number of factors and scree plots to determine whether fewer factors were appropriate.
Scree plots are provided (Figures 1 and 2) to illustrate how clearly and consistently a single-
factor solution was indicated.
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Factor rotation was designed to simplify and clarify the data structure when multiple factors
exist. Because all exploratory factor analyses indicated a single-factor solution, no rotation
was needed.
RESULTS
Psychometric Properties of the Two Batteries
Data structure—Psychometric aspects of the data were examined using exploratory factor
analysis separately on baseline data for each battery. A single-factor solution was indicated
regardless of extraction method. Scree plots of principal axis factoring are presented in
Figure 1 for CATIE and BACS domains. Furthermore, according to guidelines regarding the
proportion of explained variance (Gorsuch, 1983), a single-factor solution is the only
appropriate solution when any factor accounts for more the 40% of the total variance,
regardless of the size of additional factors. As can be seen in Table 3, all baseline factor
analyses met this criterion as a single factor explained 48%, 63%, and 50% of total variance
in baseline CATIE, BACS, and combined data from both batteries, respectively.
Given that data from both batteries were characterized by a single-factor solution, domain
scores from both batteries were combined for factor analysis to examine whether a unitary
dimension encompassed both batteries, and whether unitary dimensions underlying each
battery were relatively independent. Again, a single-factor solution was indicated by scree
plots (Figure 1) and percent of variance explained (Table 3), regardless of extraction
method. Test scores from both batteries, rather than domains scores, were also submitted to
factor analysis to examine whether a single-factor solution was applicable at the test level.
Consistent with domain level solutions, and regardless of extraction method, a single-factor
solution was indicated. Factor loadings (Table 4) showed that several tests from both
batteries had high to medium loadings on the generalized factor, whereas only tests from the
CATIE showed low or nonsignificant loadings on the generalized cognitive factor (without
independently emerging as unique factors).
The presence of a single factor underlying the baseline cognitive data in both batteries may
indicate that a single-composite index is the most appropriate starting point for evaluating
cognitive change in treatment studies. However, it is unclear whether the factor structure of
change after treatment is comparable to the generalized cognitive factor characterizing
baseline performance, or whether the factor structure of cognitive change is multifactorial.
This was empirically evaluated by means of exploratory factor analysis of domain change
indices, and the findings again indicated single-factor solutions (see Figure 2), regardless of
extraction method. When domain change indices from both batteries were considered
together, factor analysis again indicated a unitary factor structure. Although the explained
variance (25.52–38.64%) was below 40% (Table 5), this may be attributed to the range
restriction associated with difference scores and the increased proportion of error variance in
the data. Regardless, scree plots show a clear drop in eigen values after the initial factor was
extracted from each battery. When the two batteries were combined and factor analyzed, a
single-factor solution became more evident, even with three factors exceeding 1.0 eigens.
These findings using the CATIE and BACS batteries indicated that both baseline
neuropsychological performance and neuropsychological change after treatment with
atypical antipsychotic medications were simple in factor structure in the current sample of
patients in the early course of schizophrenia, and that both baseline abilities and change
following treatment using these batteries are best represented by a general neurocognitive
ability factor.
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Test–retest reliability—When test–retest reliability is evaluated with intraclass
correlations (ICCs) in the context of a treatment study, reliability of measurement can be
lowered both by intrinsic unreliability in the measures and also by treatment effects.
However, ICCs still provide a useful estimate of the consistency of performance in
composite and domain scores. As can be seen in Table 2, intraclass correlations ranged
from .61 to .89, and were generally strong within each battery and across similar domains.
These findings are consistent with previously reported BACS test–retest coefficients in
schizophrenia patients who had not undergone a change in drug treatment status between
evaluations (Keefe et al., 2004).
Sensitivity to change—Effect size estimates were used to assess the sensitivity of each
battery to change in test performance after treatment at the composite, domain, and
individual test level. Specifically, Cohen’s d (Cohen, 1988) was computed by comparing
normalized Z scores (not raw score data) for baseline and follow-up. Effect sizes of
measured change ranged from small to medium for both tests and domain scores in each
battery (see Table 2). This was consistent with modest effect sizes for neuropsychological
change reported in meta-analytic studies and larger multisite studies (Harvey et al., 2000;
Johnson-Selfridge and Zalewski, 2001; Keefe et al., 1999; Woodward et al., 2005).
Efficiency of detecting change—In terms of the amount of testing needed to derive a
meaningful estimate of cognitive abilities in schizophrenia and to detect cognitive change
following treatment, one implication of a generalized deficit model is that a brief battery
may be sufficient if it can reliably estimate global composite abilities. To directly compare
how efficiently components of each battery predicted global change from baseline to follow-
up testing, separate regressions were completed for each battery using a weighted global
neuropsychological change index. To reduce the potential for measures with low factor
loadings to bias the results, this weighted global composite was empirically guided by the
exploratory factor analysis. Specifically, each domain was weighted according to its
corresponding single-factor loading before domains from both batteries were combined into
a single index of global change and used as the criterion variable. Four domains/predictors
were entered for regression analysis of the BACS battery, and six domains/predictors were
entered in a separate analysis of the CATIE battery. Predictors were entered one at a time in
order of baseline factor loadings. Both batteries explained similar levels of cognitive change
in aggregate (CATIE: R2 =.74, F =104.02, df =6212, p < .001; BACS: R2 = .76, F = 166.58,
df = 4214, p < .001), yet the BACS achieved this in a much shorter period of test
administration time. Thus, the extra 50–60 min of administration time for the CATIE battery
failed to enhance the prediction of global cognitive change (Figure 3).
DISCUSSION
This study was designed to evaluate, in a large sample of primarily first episode
schizophrenia patients, the psychometric characteristics of two prominent
neuropsychological batteries used in the evaluation of cognitive change following
antipsychotic treatment. Exploratory factor analysis indicated that a single dimension of
generalized cognitive performance underlies pretreatment neuropsychological abilities in
early schizophrenia. Cognitive change, as assessed by both batteries, was also characterized
by a unitary generalized factor of the neuropsychological tests administered.
The finding of a generalized factor representing baseline deficits and change after treatment
suggests that relatively brief neuropsychological assessment batteries may be sufficient to
reliably assess global cognitive abilities and change in this generalized dimension after
treatment. Indeed, regression analysis evaluating the efficiency for estimating global
cognitive change revealed that, while both accounted for a similar portion of total variance
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in global neuropsychological change, the BACS battery did so in a fraction of the
administration time (BACS: 31 min; CATIE: 86 min).
Factor Structure of Neuropsychological Batteries
This is the first study to evaluate neuropsychological constructs underlying change
following treatment, and the findings also indicated a unitary factor underlying baseline
performance and change in performance after treatment in the BACS and CATIE batteries.
The generalized neuropsychological factor observed may reflect the complexity and
multidimensional characteristics of many neuropsychological tests, which often evaluate
multiple discrete cognitive processes simultaneously. Should the integrity of one component
be compromised, impaired performance can occur in multiple tests and the net result is a
sensitive but not necessarily specific measure.
With more specific measures, perhaps more directly linked to neurophysiological processes,
additional variance in treatment response could be explained and separable factors defined.
However, it is unclear whether other neuropsychological batteries, especially large ones,
would produce similar findings. However, the present findings distinctly show that no
separable group of deficits underlie performance on the CATIE and BACS batteries in the
early course of schizophrenia, and data are not yet available to indicate that other approaches
will provide a more complex factor structure for cognitive response to antipsychotic drugs.
Thus, when evaluating the effect of atypical antipsychotics on the neuropsychological
measures widely accepted as reliable and valid indicators of cognitive dysfunction in
schizophrenia (Buchanan et al., 2005), a brief battery may be sufficient for estimating the
broad cognitive factor underlying cognitive change following treatment.
The current findings are exploratory, by definition, and replication is needed in independent
samples using theory driven confirmatory factor analysis. Indeed, before definitive
conclusions can be drawn regarding a simple factor structure for neuropsychological
abilities in schizophrenia and the impact of antipsychotic treatments, support is needed from
both chronic and first episode samples using a broader range of tests. Currently, the
literature regarding the factor structure underlying neuropsychological abilities in
schizophrenia has produced mixed findings, perhaps related to variation in the use of factor
analytic approaches. Multi-factor models have been supported in schizophrenia using
confirmatory factor analysis of the Wechsler Adult Intelligence Scale Revised (WAIS-R,
Wechsler, 1981; Allen et al., 1998) and exploratory factor analysis of brief (Keefe et al.,
2004) and extended neuropsychological batteries with and without measures of intelligence
and memory (Gladsjo et al., 2004; Green et al., 2002; Hobart et al., 1999). However, several
studies reporting multifactor solutions in schizophrenia have extracted factors with eigen
values less than 1.0 or failed to use the scree test in determining the number of factors to
retain (Green et al., 2002; Hobart et al., 1999; Keefe et al., 2004).
There is a preponderance of evidence supporting a unitary dimension underlying a wide
range of neuropsychological measures in chronic and early course schizophrenia samples
using both exploratory and confirmatory factor analysis. For example, Strauss and
Summerfelt (2003) reported that a single factor sufficiently accounted for
neuropsychological test performance in schizophrenia patients. When comparing WAIS-III/
Wechsler Memory Scale-III (WMS-III) performance in outpatients with schizophrenia and
healthy individuals, a single common factor accounted for the majority of patient deficits,
and data from specific domains accounted for very little unique between-group variance
(Dickinson et al., 2004). Additionally, despite extracting a three-factor solution from a
lengthy neuropsychological battery, Green and colleagues argued that a large reliable
general factor (accounting for 45% of total variance) justified combining all variables into a
single composite to evaluate pharmacological treatment effects (Green et al., 2002). In a
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confirmatory factor analysis of cognitive data from the CATIE study (1332 schizophrenia
spectrum patients), unitary and multifactor models were directly compared and a single-
factor model provided a better fit than a five-factor model (Keefe et al., 2006). A principal
components analysis of these data also supported a unitary factor, with just one component
exceeding 1.0 eigens (Keefe et al., 2006). Similarly, a hierarchical model representing a
broad cognitive dimension, rather than a multifactor model of separate latent cognitive
factors, was a better fit for performance on individual tests in chronic schizophrenia
(Dickinson et al., 2006). Thus, to the extent that neuropsychological measures can inform
the nature of neurocognitive dysfunction in schizophrenia, available evidence supports a
unitary structure underlying a wide range of neuropsychological measures using a variety of
methodologies in well-designed/executed studies with diverse schizophrenia samples. Thus,
consistent with findings from the present study, the multifactor models of
neuropsychological performance in healthy individuals (Tulsky & Price, 2003) have not
generalized to schizophrenia samples. One explanation for this difference may be that
disturbances associated with the disorder are similar across higher cognitive abilities, and
that the magnitude of this generalized “disease” effect overwhelms the more modest normal
independence of various neuropsychological abilities.
Psychometrics and Efficiency
Traditionally, clinical neuropsychology has emphasized comprehensiveness, but brevity
becomes important in large clinical trials due to cost and differential attrition (more severely
ill patients are less likely to complete long batteries or consistently perform at their ability
level). The current findings suggest that shorter batteries may be sufficient to reliably
estimate broad neuropsychological ability and cognitive change after treatment with atypical
antipsychotic medication in early schizophrenia. The nature of a generalized, unitary factor
of neuropsychological abilities, at least as assessed by these two batteries, may partially
account for why the shorter BACS battery compared so favorably to the CATIE battery.
Direct comparison of reliability, albeit in the context of a clinical trial, revealed good overall
reliability for each battery and comparable ICCs among common domains. The benefits of
brevity, of course, are meant to apply to research studies where an assumption of
generalized deficits seems to adequately characterize data at the group level. This may not
be the case for individual patients in a clinical context.
From a psychometric perspective, although the BACS and CATIE batteries had similar
reliability and sensitivity to change after treatment, each battery demonstrated some relative
strengths and weaknesses. The most salient weakness in the CATIE battery was the WCST.
Not only did the WCST composite fail to load robustly on the single-factor solution, but
WCST scores failed to emerge as an independent cognitive factor (see Table 4) and none of
the WCST variables were particularly sensitive to change after treatment (the collective
effect of antipsychotic treatment and practice; Table 2). As a whole, the CATIE: Reasoning
and Problem Solving domain (which contains the WCST) produced the lowest domain
reliability in the battery, low factor loadings, and poor sensitivity to cognitive change while
taking nearly one-third of the battery administration time. Although reasoning and problem
solving was the least reliable BACS domain (perhaps illustrating the effects of repeat
exposure to problem-solving paradigms in which a single exposure may fundamentally alter
subsequent performance, despite alternate forms), the Tower of London loaded moderately
on the general cognitive factor and was more sensitive to change effects (effect size = .39)
than other reasoning and problem-solving tests.
Recently, social cognitive processing has garnered increased interest in schizophrenia
outcome studies (Corcoran, 2001; Kee et al., 2003; Lancaster et al., 2003). To our
knowledge, this is the first study to include social cognition in factor analysis of a
schizophrenia spectrum sample. Factor loadings and change effect sizes for social cognition
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were relatively small, suggesting that this measure of social cognition was less sensitive to
changes after treatment than was seen with other domains. This finding was consistent with
previous reports indicating no significant improvement in emotion perception following
antipsychotic treatment of first episode psychosis (Herbener et al., 2005). From an efficiency
perspective, evaluation of social cognition added little to the assessment of the global
cognition factor underlying the BACS or CATIE or sensitivity to antipsychotic treatment
effects of cognition. However, this was the only measure of its kind, and the notion that
social cognition might load with a strictly neurocognitive factor may be premature. Indeed,
improved sampling of social cognition components is needed to more accurately evaluate
the independence of a social cognition factor.
The most salient weakness of the BACS was the poor sensitivity of Digit Sequence to
change. Although this is a brief measure with strong reliability and a strong correlation with
the general neuropsychological factor, it was relatively insensitive to cognitive change after
antipsychotic treatment. In contrast, Letter–Number Sequencing of the CATIE matched
Digit Sequencing in terms of factor loadings, administration time, and domain reliability, but
provided greater sensitivity to the effects of atypical antipsychotic treatment and practice.
Verbal learning and memory deficits have become a hallmark of schizophrenia research, and
an efficient means for evaluating the overall level of cognitive dysfunction in the disorder
(Hill et al., 2004b; Paulsen et al., 1995; Saykin et al., 1991). Despite good reliability and
moderate to large factor loadings, verbal list learning was only modestly sensitive to change
following atypical antipsychotic treatment in both batteries. This was consistent with
previous findings of stable verbal memory deficits over time (Hawkins & Wexler, 1999; Hill
et al., 2004a; Hoff et al., 1999). Thus, aside from documenting expected deficits in the
disorder, evaluation of verbal learning may have limited utility in detecting cognitive effects
of atypical antipsychotics.
Limitations
Each instance of factor analysis indicated a single-factor solution, but a large amount of
variance (typically;50%) remained unexplained. Although this is not unusual for a single-
factor solution, there remains the possibility that adding tests or domains might help define
additional factors. The unitary dimension of neuropsychological performance and change
observed in the present study may be limited merely to the domains assessed, the measures
used to assess these domains, or the manner in which domains were assessed. Furthermore,
it is possible that measures sensitive to multiple independent factors were not adequately
assessed by either battery used in the present study, and a more extensive battery with
multiple tests of each domain might uncover a more differentiated factor structure. Both
batteries used in the present study have a limited number of tests within each domain, and a
minimum of three tests per domain is recommended for adequate coverage of multiple latent
variables (Kenny et al., 1988). However, one benefit of evaluating factor structure at the test
level, using combined data from both batteries, was broader coverage of several domains.
These findings also indicated a single dimension (Table 4).
There are potential limitations to the generalizability of the current findings. All patients in
the present study were early in the course of illness, thereby reducing the potential effects of
chronicity on treatment responsiveness. It is unclear whether the present findings would
generalize to chronic patients with more persistent dysfunction, individuals in the prodrome
phase, or other diagnostic groups. Also, although effects of the three atypical antipsychotics
were similar, generalizability to other treatments cannot be assumed. Finally, prior
medication exposure may attenuate treatment effects. That is, Table 1 noted that, however
brief, the majority of patients had prior exposure to antipsychotic medication. Although
previous medications were tapered, a washout sufficient to clear all antipsychotic drugs
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before baseline testing was not ethically viable. Thus, prior antipsychotic treatment may
have reduced the extent or simplified the factor structure of change after treatment, to a
degree. Last, because a placebo control group cannot be used ethically with acutely
psychotic first episode patients, change measures at follow-up include influences of both
drug and practice effects. This too may have led to an underestimate of multifactorial change
in cognitive abilities after treatment.
Practical Implications
The BACS battery demonstrated a distinct advantage in efficiency of assessing global
cognitive treatment outcome over the CATIE battery. It accounted for a similar proportion
of global change in generalized cognitive performance after treatment in approximately one-
third the administration time with a minimal cost in sensitivity to aggregate antipsychotic
effect on measured cognition (BACS ES =.44, CATIE ES =.50). Rather than inherent flaws
with the CATIE battery, this finding may simply reflect the relative ease of reliably and
validly assessing a generalized dimension with fewer tests, and the limit in incremental
knowledge provided by additional test data in this population.
Shorter batteries such as the BACS may provide an adequate estimate of generalized
cognitive deficits in studies of antipsychotic treatment on functionally important
neuropsychological deficits. The multifactorial approach of the MATRICS consensus
battery (Neuchterlein et al., 2004), which aims to independently assess six cognitive
domains, may not be necessary for evaluating antipsychotic effects on cognition. Further
studies are needed to fully demonstrate the utility of such larger test batteries in assessing
cognitive outcomes relative to the brief batteries. Multifactor approaches may prove to be a
crucial strategy for drug evaluation, particularly if potential procognitive adjunctive
treatments are predicted to have effects on specific receptor systems and functional circuits
as well as the cognitive abilities they support. For example, if a new nicotinic agent
primarily improves attention, then multiple tests of attention may be more useful in
assessing change than tests of general cognitive ability. Change in attention may be more
pronounced than change in other domains, and then latent factor structure of change after
treatment may be different than with antipsychotic treatments. Adequate assessment of
domains targeted by new treatments will be crucial components to cognitive batteries
evaluating possible differential effects of adjunctive treatments in the context of clinical
trials.
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Scree plots illustrating single factor solutions for baseline cognitive data of CATIE and
BACS domains separately and combined
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Scree plots of domain change scores illustrating single factor solutions for treatment-related
change in each battery separately and when domain change scores were combined across
batteries for factor analysis
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Efficiency of the CATIE and BACS batteries in accounting for variance in the global
neuropsychological change index as a function of administration time
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Table 3
Principal axis factor loadings for baseline cognitive data of CATIE and BACS domains separately and when
domains from both batteries were combined
Factor loadings
CATIE domains BACS domains All domains
CATIE
 Processing .78 .82
 Reasoning .40 .39
 Verbal Memory .62 .65
 Working Memory .80 .80
 Vigilance .70 .68
 Social Cognition .32 .31
BACS
 Processing .79 .81
 Reasoning .55 .55
 Verbal Memory .75 .77
 Working Memory .76 .77
Statistics
Explained Variance 48.07% 63.09% 50.21%
Determinant .20 .28 .01
KMO .82 .78 .89
Bartlett’s Test of Sphericity 583.36, df =15, p <.001 468.66, df =6, p <.001 1800.38, df =45, p <.001
Note. CATIE =Clinical Antipsychotic Trials of Intervention Effectiveness; BACS =Brief Assessment of Cognition in Schizophrenia; KMO
=Kaiser-Meyer-Olkin.
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Table 4
Principal axis factor loadings of baseline performance for individual tests from both the CATIE and BACS
batteries
Test variable Factor loadings
Digit Symbol Test (C) .77
List Learning (B) .76
Letter–Number Sequencing (C) .76
Digit Sequencing (B) .76
Symbol Coding (B) .76
CATIE Verbal Fluency (C) .72
CPT–Identical Pairs (C) .69
Hopkins List Learning Test (C) .64
BACS Verbal Fluency (B) .58
Grooved Pegboard (C) .55
Tower of London (B) .55
Spatial Working Memory (C) .53
Token Motor Task (B) .51
WISC-III Mazes (C) .41
Emotion Discrimination (C) .31
Wisconsin Card Sorting Test (C) −.01
Note. 41.09% of Total Variance Explained. Determinant =.001. Kaiser-Meyer-Olkin =.90. Bartlett’s Test of Sphericity: 2678.76, df=120, p<.001.
(C): Test from CATIE battery; (B): test from BACS battery. CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness;
CPT=Continuous Performance Test; BACS=Brief Assessment of Cognition in Schizophrenia; WISC-III = Wechsler Intelligence Scale for
Children–Third Edition.
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Table 5
Principal axis factor loadings of domain change scores at the 12-week follow-up for CATIE and BACS
domains separately and when domain change scores from both batteries were combined
Factor loadings
CATIE domains BACS domains All domains
CATIE
 Processing .49 .69
 Reasoning .20 .16
 Verbal Memory .31 .27
 Working  Memory .54 .42
 Vigilance .57 .50
 Social Cognition .18 .16
BACS
 Processing .64 .69
 Reasoning .22 .13
 Verbal Memory .51 .47
 Working Memory .33 .37
Statistics
Explained Variance 29.57% 38.64% 25.52%
Determinant .69 .82 .29
KMO .64 .61 .70
Bartlett’s Test of Sphericity 80.09; df =15; p <.001 42.95; df =6; p <.001 266.36; df =45; p <.001
Note. CATIE =Clinical Antipsychotic Trials of Intervention Effectiveness; BACS =Brief Assessment of Cognition in Schizophrenia; KMO
=Kaiser-Meyer-Olkin.
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